Roche Diabetes Care Confirms Continued Supply of Accu-Chek Aviva and Accu-Chek Aviva Plus Test Strips
INDIANAPOLIS—Roche Diabetes Care, makers of ACCU-CHEK products and services, is pleased to confirm the continued availability of its ACCU-CHEK Aviva test strip and since November 28, 2011 the ACCU-CHEK Aviva Plus test strip. Any claim related to the backorder of ACCU-CHEK Aviva or ACCU-CHEK Aviva Plus testing strips is incorrect.
Roche produces more than three billion ACCU-CHEK test strips each year at its North America facilities, which ensures a constant, uninterrupted supply to the U.S. market. These blood glucose test strips are currently available for purchase through all authorized Roche Diabetes Care distributors – a list of which can be found at https://rxvp.accu-chek.com/welcome/adr_list. Customers are encouraged to contact firstname.lastname@example.org with any information about unauthorized distributors misrepresenting the availability of the ACCU-CHEK Aviva or ACCU-CHEK Aviva Plus test strip product.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients’ condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Todd A. Siesky
Public Relations Manager
Roche Diabetes Care
(317) 521-3966 O
(317) 361-7637 C